domingo, 11 de junio de 2017

Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors. - PubMed - NCBI

Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors. - PubMed - NCBI



 2017 Apr 5. doi: 10.18632/oncotarget.16859. [Epub ahead of print]

Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors.

Abstract

Poly(ADP-ribose) polymerases are a family of DNA-dependent nuclear enzymes catalyzing the transfer of ADP-ribose moieties from cellular nicotinamide-adenine-dinucleotide to a variety of target proteins. Although they have been considered as resident nuclear elements of the DNA repair machinery, recent works revealed a more intricate physiologic role of poly(ADP-ribose) polymerases with numerous extranuclear activities. Indeed, poly(ADP-ribose) polymerases participate in fundamental cellular processes like chromatin remodelling, transcription or regulation of the cell-cycle. These new insight into the physiologic roles of poly(ADP-ribose) polymerases widens the range of human pathologies in which pharmacologic inhibition of these enzymes might have a therapeutic potential. Here, we overview our current knowledge on extranuclear functions of poly(ADP-ribose) polymerases with a particular focus on the mitochondrial ones and discuss potential fields of future clinical applications.

KEYWORDS:

PARP; cancer; mitochondria; signaling; targeted therapy

PMID:
 
28430591
 
DOI:
 
10.18632/oncotarget.16859
Free full text

No hay comentarios:

Publicar un comentario